Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

By sjmartinez • April 11, 2025

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown J, Pienkowski T, Bee V, Casas M, Polonio Ó, Bezares S, Slamon D. Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies. Int J Cancer. 2025 Apr 10. doi: 10.1002/ijc.35432. Epub ahead of print. PMID: 40207789.

Tags: body mass index, docetaxel, early‐stage breast cancer, Hematology/Oncology, paclitaxel, Pooled analysis, Publications, survival

Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of Disease

Fine SA, Lim SY, Siena NM, de Jesus AB, Goh T, Markus L, Russell TA, Kendal JK, Lofftus SY, Shehata MS, Dao HB, Lee A,[...]

Elevated Adrenocorticotropic Hormone After Adrenalectomy or Adrenal Ablation and Immune Checkpoint Inhibitors: Adrenal Insufficiency Is Not Always the Culprit

Shabsovich D, Kathuria-Prakash N, Zhang J, Cabral M, Lopez L, Sumal A, Drakaki A. Elevated Adrenocorticotropic Hormone After Adrenalectomy or Adrenal Ablation and Immune Checkpoint[...]

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)

Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Couselo EM, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Wise-Draper TM, Bowles TL, Tsai[...]